US4585742A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody with specificity to human small cell carcinoma and use thereof
Assignee: Dana Farber Cancer Institute Inc
•
Filing: 1983-12-14
•
Granted: 1986-04-29
•
Expires: 2003-12-14
Abstract
Abstract Monoclonal antibody reactive with SCC cells and unreactive with human neuroblastoma cells, human squamous cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells.
Inventors
- 👤 Samuel D. Bernal
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 14:35
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3023; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/813; Y10S436/821; Y10S530/00; Y10S530/863; Y10S530/864
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
77 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in a radioimmunoassay in which said cells are incubated with said monoclonal antibody and a radiolabeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 2
Dependent Claim
77 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in a radioimmunoassay in which said cells are incubated with said monoclonal antibody and a radiolabeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 3
Dependent Claim
15 words
The antibody of claim 1, wherein said antibody is of the IgM or IgG2 isotype.
Claim 4
Dependent Claim
23 words
The antibody of claim 1, wherein said antibody recognizes an approximately 25,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 5
Dependent Claim
14 words
The antibody of claim 1, wherein said antibody is coupled to a cytotoxic agent.
Claim 6
Dependent Claim
14 words
The antibody of claim 1, wherein said antibody is labeled with a detectable label.
Claim 7
Dependent Claim
10 words
The antibody of claim 5, wherein said antibody is radiolabeled.
Claim 8
Dependent Claim
11 words
The antibody of claim 5, wherein said antibody is fluorescently labeled.
Claim 9
Dependent Claim
23 words
The antibody of claim 1, wherein said antibody is capable, in the presence of complement, of lysing small cell carcinoma cells in vitro.
Claim 10
Dependent Claim
13 words
The monoclonal antibody produced by the hybridoma cell given ATCC Accession No. HB8462.
Claim 11
Dependent Claim
13 words
The monoclonal antibody produced by the hybridoma cell given ATCC Accession No. HB8462.
Claim 12
Dependent Claim
27 words
A hybridoma cell capable of producing a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462.
Claim 13
Dependent Claim
27 words
A hybridoma cell capable of producing a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462.
Claim 14
Dependent Claim
8 words
The hybridoma cell given ATTC Accession No. HB8462.
Claim 15
Dependent Claim
8 words
The hybridoma cell given ATTC Accession No. HB8462.
Claim 16
Independent Claim
72 words
A method of detecting the presence of small cell carcinoma cells in a human patient comprising incubating a cell-containing clinical sample from said patient with a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB 8462 under conditions sufficient to permit formation of immune complexes and detecting said immune complexes as an indication of the presence of small cell carcinoma cells.
Claim 17
Independent Claim
72 words
A method of detecting the presence of small cell carcinoma cells in a human patient comprising incubating a cell-containing clinical sample from said patient with a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB 8462 under conditions sufficient to permit formation of immune complexes and detecting said immune complexes as an indication of the presence of small cell carcinoma cells.
Claim 18
Independent Claim
48 words
A method of lysing small cell carcinoma cells in a clinical sample comprising incubating said sample with a monoclonal antibody having the immunological identifying characteristic of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 in the presence of complement under conditions which permit lysis.
Claim 19
Independent Claim
48 words
A method of lysing small cell carcinoma cells in a clinical sample comprising incubating said sample with a monoclonal antibody having the immunological identifying characteristic of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 in the presence of complement under conditions which permit lysis.
Claim 20
Independent Claim
58 words
A method of lysing small cell carcinoma cells in a clinical sample from a patient comprising incubating said sample with an immunotoxin consisting of (1) a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 and (2) covalently bound thereto a cytotoxin; under conditions with permit lysis.
Claim 21
Independent Claim
58 words
A method of lysing small cell carcinoma cells in a clinical sample from a patient comprising incubating said sample with an immunotoxin consisting of (1) a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 and (2) covalently bound thereto a cytotoxin; under conditions with permit lysis.
Claim 22
Dependent Claim
79 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in an indirect immunofluorescence assay in which said cells are incubated with said monoclonal antibody and a fluorescein-labeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 23
Dependent Claim
79 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in an indirect immunofluorescence assay in which said cells are incubated with said monoclonal antibody and a fluorescein-labeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-28 | 1989-10-28 | 1990-04-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-28 | 1993-10-28 | 1994-04-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-28 | 1997-10-28 | 1998-04-29 | $7700.00 | Window Closed / Lapsed |